Viewing Study NCT01922102


Ignite Creation Date: 2025-12-25 @ 3:56 AM
Ignite Modification Date: 2026-02-24 @ 8:50 AM
Study NCT ID: NCT01922102
Status: COMPLETED
Last Update Posted: 2019-06-24
First Post: 2013-08-12
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Sponsor: Novartis Pharmaceuticals
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic … View
Keywords:

Keywords

Keyword Brief Keyword Text View
None vision loss,PM,CNV,ranibizumab,verteporfinPDT,Brilliance View